CSF2 and COVID-19: Lastly, all the CAR-NK cells in this trial secrete GM-CSF neutralizing scFv antibodies, since this cytokine has a known role in CRS in cancer patients treated with CAR-T cells (172), and has been shown to be correlated with COVID-19 disease severity in association with pathogenic CD4+ Th1 cells (173).